Collaboration with Contract Development and Manufacturing Organizations (CDMOs) has played a crucial role in advancing paediatric oncology treatment.
CDMOs are companies that specialize in the development and manufacturing of pharmaceuticals and biologics on behalf of other companies, including pharmaceutical companies and research institutions. Here are some ways CDMOs have contributed to advancements in paediatric oncology treatment:
Formulation Development: CDMOs can assist in the development of age-appropriate drug formulations for paediatric patients. This includes creating liquid formulations or pediatric-friendly dosage forms, which can be easier for children to take compared to traditional tablets or capsules
Drug Repurposing: CDMOs can help identify existing drugs that can be repurposed for paediatric oncology. This can significantly speed up the drug development process as safety and toxicity profiles of these drugs are already known
Pharmacokinetic Studies: CDMOs can conduct pharmacokinetic studies to determine how drugs are absorbed, distributed, metabolized, and excreted in paediatric patients. This information is critical for optimizing dosing regimens
Scale-Up and Manufacturing: Once a potential paediatric oncology drug is identified, CDMOs can scale up the manufacturing process to ensure a consistent and high-quality supply. This is important for clinical trials and eventual commercialization
Regulatory Expertise: CDMOs often have extensive regulatory expertise, helping pharmaceutical companies navigate the complex regulatory landscape surrounding paediatric drug development. They can assist in preparing regulatory submissions and addressing FDA requirements
Quality Control: Ensuring the quality and safety of paediatric oncology drugs is paramount. CDMOs have the infrastructure and expertise to implement rigorous quality control measures to meet regulatory standards
Clinical Trial Support: CDMOs can also support clinical trials by providing drug product for investigational studies. This includes manufacturing, packaging, labeling, and distributing the drug products to various trial sites
Specialized Facilities: Some CDMOs have specialized facilities for manufacturing advanced therapies such as gene therapies and immunotherapies, which are increasingly being explored for paediatric oncology
Customized Solutions: CDMOs can offer customized solutions tailored to the unique needs of paediatric oncology research, such as small batch sizes, flexible manufacturing schedules, and specialized packaging
Cost Efficiency: By outsourcing drug development and manufacturing to CDMOs, pharmaceutical companies can often reduce costs and allocate resources more efficiently, which is particularly important in paediatric oncology where the patient population is smaller compared to adult oncology
In conclusion, CDMOs play a pivotal role in advancing paediatric oncology treatment by expediting drug development, ensuring quality, and facilitating regulatory compliance. Their expertise and capabilities contribute significantly to the development of safer and more effective treatments for paediatric cancer patients.
Mantell Associates is a specialist Pharmaceutical and Life Sciences headhunting firm. To find out how we can assist with your business requirements, get in touch with us at +44 2038 547700.
Sources:
PubMed: https://pubmed.ncbi.nlm.nih.gov/
National Cancer Institute (NCI): https://www.cancer.gov/
American Cancer Society (ACS): https://www.cancer.org/
Children's Oncology Group (COG): https://childrensoncologygroup.org/
FDA's Oncology Center of Excellence: https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence